FIELD: chemistry.
SUBSTANCE: invention relates to use of the compound of formula (I) for preventing or treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH), where A is OH or OCH3; R represents H, CH3 or cyclopropylmethyl; X is an oxygen atom, Y is CH2 or oxygen, Z is H or OH, and where the use of the compound of formula (I) leads to reduced hepatic fibrosis, which is a sign of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
(I).
EFFECT: technical result is the possibility of using the compound of formula (I) for preventing or treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
14 cl, 1 tbl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| COMPOSITIONS CONTAINING 15-OHEPA AND METHODS OF USING SAME | 2014 |
|
RU2671208C2 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| STRUCTURALLY ENHANCED OXYGEN-CONTAINING FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2820995C2 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
